Dwarfism

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
1
r-hGHPhase 41 trial
Active Trials
NCT01157793CompletedEst. Feb 2005
HM
Hua MedicineChina - Shanghai
1 program
1
Recombinant Human Growth Hormone InjectionPhase 31 trial
Active Trials
NCT03535415Unknown68Est. Sep 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Merck & Co.r-hGH
Hua MedicineRecombinant Human Growth Hormone Injection

Clinical Trials (2)

Total enrollment: 68 patients across 2 trials

A Multicentre, Randomised, Open-label, Controlled Study to Evaluate the Effects of Saizen® on Cardiac Function in Growth Hormone Deficient(GHD) Subjects During the Transition Phase From Childhood to Adulthood

Start: Sep 2003Est. completion: Feb 2005
Phase 4Completed
NCT03535415Hua MedicineRecombinant Human Growth Hormone Injection

A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation

Start: Jun 2018Est. completion: Sep 202168 patients
Phase 3Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space